Vext Science, Inc.

Vext Science, Inc., through its various subsidiaries, operates as a comprehensive agricultural technology, services, and property management company within the United States cannabis sector. Its operations span the entire product lifecycle, from cultivating and extracting to manufacturing and distributing THC and CBD vape cartridges, concentrates, and edibles. The company also manages retail dispensaries and conducts wholesale distribution of cannabis-derived THC and hemp-derived CBD products, marketed under its Vapen and Pure Touch Botanicals brands. Expanding its edible range, Vext Science offers various THC-infused items under the Vapen Kitchens brand, including Vapen Clear products, chocolate bars, syrups, snacks, candies, and gummies. Incorporated in 2015, the company was formerly known as Vapen MJ Ventures Corporation, adopting its current name, Vext Science, Inc., in November 2019. Its headquarters are located in Phoenix, Arizona.

Vext Science, Inc. trades as VEXT.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $52.27M of revenue and -$18.31M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Vext Science, Inc. can be compared against peers such as The Cannabist Company Holdings Inc., C21 Investments Inc., Decibel Cannabis Company Inc., 1CM Inc., iAnthus Capital Holdings, Inc., InnoCan Pharma Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $64.40M, beta of 0.76, and return on equity of -33.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

VEXT.CN currently shows total debt of $34.97M and beta of 0.76. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.vextscience.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.